Mindset Pharma Selects Treatment-Resistant Depression and End of Life Cancer Angst as Indications for MSP-1014, its NoveHow Will The Data Protection Ruling On Ketamine Impact Psychedelic Novel Drug Development Moving Forward?Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic AnalogsSilo Pharma Advances Psychedelic Patent PortfolioTryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of FloridaMajor Psychedelic Clinical Trial Data Is Right Around The CornerPsychedelic Drug Development Companies Are Leveraging Bolt On MedTech Acquisitions To Create A More Robust Patient Care 7 Psychedelic Clinical Trials Underway That Investors Should Keep On Their RadarNuminus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into PSilo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide PatentTryp Therapeutics Announces Q3 2021 Financial ResultsKetamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured VeteransWake Network, Inc. and the Lieber Institute for Brain Development Announce Research CollaborationTryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of MichiganNuminus Wellness Reaches Major Milestone With MAPS Sponsored MDMA StudyNuminus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSDPsyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical TrialTryp Therapeutics Partners with the University of Michigan to Evaluate Proprietary FormulationsPsyched Wellness Commences Next Pre-Clinical Study on AME-1Atai Life Sciences Is Setting The Standard For Psychedelic Drug Development

Join the top platform for cannabis stock analysis.

Mushroomstocks is a subscription service who provides research, analysis, and news on publicly traded cannabis companies. Our goal is to educate subscribers on the risks and rewards of investing in cannabis companies, by separating the leading from the lagging companies.

We offer premium and free services to our users. Premium users have access to market data, stock analysis, and company research on Mushroomstocks’s investing universe. Free users have access to our blog articles and are less interested in investing in the stocks levered to the growth of the cannabis industry.

No, Mushroomstocks is not a broker, broker-dealer or market-maker. The information found on the website is intended to be used for informational purposes only and not be interpreted as a solicitation or recommendation to buy or sell stocks.

Yes, your monthly membership will automatically renew every month and you will receive an email prior to your renewal.

Many of the cannabis companies are ancillary businesses are levered to the growth of the industry. These companies do not actually touch the plant. Cannabis companies do not go public through typical methods. The companies go public through reverse mergers. A reverse merger allows a private company to become public without having to raise capital, which simplifies the process. While conventional IPOs can take months to materialize, reverse mergers can take only a few weeks to complete (in some cases, in as little as 30 days). In a reverse merger, investors of the private company acquire a majority in the shares of the public shell company, which is then merged with the purchasing entity.

The SEC considers any stock that costs less than $5 per share a penny stock. Most penny stocks trade on OTCBB and Pink Sheets, which are vulnerable to market manipulation due to the lack of regulation. Companies that are listed on a SEC regulated exchange (i.e. NYSE, NASDAQ, AMEX) must meet certain financial reporting and price requirements to be allowed such listing.

Mushroomstocks developed a proprietary algorithm which merges technical, fundamental, momentum, and market sentiment data to yield the most comprehensive, all-inclusive analysis possible. To obtain this raw data faster than you would find elsewhere, Mushroomstocks utilizes a specialty terminal service provided by Thomson Reuters (Thomson One System) that sends us key company financials and news as soon as it hits the tape.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link